My watch list  

41 Current news of Pharmexa


You can refine your search further. Select from the filter options on the left to narrow down your results.

Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.


VaxOnco Inc, a Korean company specializing in peptide based vaccines, has acquired Pharmexa-Epimmune (Pharmexa Inc.) by the purchase of all outstanding shares from Pharmexa A/S for €440,000. VaxOnco will thus assume all rights and responsibilities relating to the Pharmexa-Epimmune patent ...


Pharmexa and Affitech to combine operations to create a new Antibody Therapeutics Company

New business to be renamed Affitech


Pharmexa A/S and Affitech AS announced that they have entered into a conditional agreement to merge the two companies by means of a share for share acquisition by Pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the merger is to transform Pharmexa from a cancer and ...


Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd


Pharmexa and KAEL Co. Ltd. of South Korea have entered into an agreement regarding GV1001 and Pharmexa´s Norwegian subsidiary Gemvax. Kael will acquire all shares of Gemvax and will thus assume all rights and responsibilities relating to the patent portfolio of GemVax including GV1001. In ...


Pharmexa appoints new Chief Executive Officer and implements further cost-saving measures


Dr. Achim Kaufhold (50) becomes new Chief Executive Officer and succeeds Jakob Schmidt. The board of directors in Pharmexa intends to nominate Jakob Schmidt as a new board member for election at the next general assembly of the company. Pharmexa is also taking further measures towards the ...


Pharmexa and Ichor Medical Systems enter into an agreement to co-develop multiple DNA vaccines delivered by electroporation


Pharmexa and Ichor have entered into an agreement to co-develop multiple DNA vaccines to combat important diseases of high unmet medical need. It is well recognized that in vivo electroporation is a promising means of enhancing the potency of DNA vaccines. The co-development programmes include a ...


Pharmexa extends and updates license agreement with H. Lundbeck A/S


Pharmexa and Lundbeck have entered into a new agreement, which is an extension of the original research and license agreement from April 2000, wherein H. Lundbeck received a global and exclusive license to PX106, a vaccine against Alzheimer's disease, developed by Pharmexa. With the updated ...


New promising results published on Pharmexa's PADRE epitope in Alzheimer's vaccine


A group of scientists from the Institute of Molecular Medicine at Huntington Beach (California) and the Institute of Brain Aging and Dementia at the University of California has published new pre-clinical data on an experimental second generation Alzheimer's vaccine incorporating Pharmexa's ...


New clinical results support telomerase vaccination in breast cancer


A group of prominent scientists from the Abramson Cancer Center and the University of Pennsylvania School of Medicine has published new clinical data on vaccination with the telomerase peptide I540 in 19 metastatic breast cancer patients. The results show that vaccination with the I540 ...


Achim Kaufhold joins Pharmexa as Executive Vice President, CSO and CMO


Professor Achim Kaufhold, M.D. (49) joins Pharmexa as Executive Vice President, Chief Scientific Officer (CSO) and Chief Medical Officer (CMO). Dr Kaufhold has spent more than 12 years in the biotech and pharmaceutical industry in senior management positions. Prior to starting up his own life ...


Pharmexa again prevails against Geron in patent appeal


In May 2004 the US biotech company Geron filed an opposition against Pharmexa's issued European patent (EP1093381) covering the telomerase vaccine GV1001. In 2005, the Opposition Division of the European Patent Office refused to grant Geron's request for invalidation of the issued patent, but ...


Page 1 From 5
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE